Feature | Lung Imaging | June 24, 2015

Mount Sinai study concludes detection of non-solid, cancerous nodules possible in 12-month intervals

low-dose CT, LDCT, lung cancer, screening, nonsolid nodules, Mount Sinai

June 24, 2015 - People who have nonsolid lung nodules can be safely monitored with annual low-dose computed tomography (CT) screening, according to a new study published online in the journal Radiology. Researchers said the findings could help spare patients from unnecessary surgery and additional imaging.

Lung nodules are small masses of tissue in the lungs that can be benign or cancerous. They are classified as solid, part solid or nonsolid, based on their appearance on CT. In nonsolid lung nodules, normal lung tissue is visible through the nodule. Nonsolid nodules are visible on CT scans of the chest, and management of them is challenging.

"Nonsolid nodules could be due to inflammation, infection or fibrosis, but could also be cancerous or a precursor of cancer," said study co-author Claudia I. Henschke, Ph.D., M.D., from the Department of Radiology at Mount Sinai School of Medicine in New York City. "For screening, we have to define which nodules need further workup and how quickly we have to do that workup."

In the new study, Henschke and colleagues analyzed results from 57,496 participants in the International Early Lung Cancer Program (I-ELCAP), a major worldwide initiative focused on reducing deaths from lung cancer. The patients underwent baseline and annual repeat screenings, and the researchers evaluated the prevalence of nonsolid nodules and their effect on long-term outcomes.

A nonsolid nodule was identified in 2,392 (4.2 percent) of the baseline screenings, and further analysis led to the diagnosis of 73 cases of cancer. A new nonsolid nodule was identified in 485 of 64,677 annual repeat screenings, or 0.7 percent, and 11 were diagnosed with Stage I cancer. Surgery was 100 percent curative in all cases, with a median follow-up since diagnosis of more than six years.

The nonsolid nodule developed a solid component-a warning sign of invasive cancer-in 22 cases prior to treatment. However, the median transition time from nonsolid to part-solid was more than two years. No cancers occurred in new nodules 15 millimeters or larger in diameter.

The findings suggest that nonsolid nodules of any size can be safely followed with low-dose CT at 12-month intervals to assess a potential transition to part-solid.

"The results show that if we see a nonsolid lung nodule of any size, we can tell people to come back in one year for another CT," Henschke said. "These findings are important for reducing unnecessary CT scans and possible biopsies or surgery in programs of CT screening for lung cancer."

One immediate benefit may be a reduction in the overtreatment of nodules, according to study co-author David F. Yankelevitz, M.D., from Mount Sinai.

"Many recommendations had been fairly aggressive with respect to nonsolid nodules," Dr. Yankelevitz said. "These results show that there is no reason to be aggressive in pursuit of cancer, so long as the nodules stay in this nonsolid form."

The study results also provide additional information to help in the shared decision-making process between physician and patient, Yankelevitz said. Patients can be assured that one-year low-dose CT screening intervals are sufficient, and also know that more aggressive treatment may be required if the nodules develop solid components.

"This is a major step forward for lung cancer screening protocols," Yankelevitz said. "It will help us cut down on the number of surgeries and unnecessary imaging tests."

For more information: www.radiology.org


Related Content

News | Enterprise Imaging

April 25, 2024 — International medical imaging IT and cybersecurity company Sectra has signed two contracts to provide ...

Time April 25, 2024
arrow
News | Radiology Business

April 23, 2024 — A diverse writing group—lead by authors at the University of Toronto—have developed an approach for ...

Time April 23, 2024
arrow
News | Magnetic Resonance Imaging (MRI)

April 17, 2024 — Hyperfine, Inc., a groundbreaking health technology company that has redefined brain imaging with the ...

Time April 17, 2024
arrow
News | Clinical Trials

April 16, 2024 — QT Imaging Holdings, Inc., a medical device company engaged in research, development, and ...

Time April 16, 2024
arrow
News | Mammography

April 12, 2024 — Bayer and Hologic, Inc. announced a first-of-its-kind collaboration to deliver a coordinated solution ...

Time April 12, 2024
arrow
News | Mammography

April 12, 2024 — GE HealthCare, a leader in breast health technology and diagnostics, will feature its latest breast ...

Time April 12, 2024
arrow
News | Population Health

April 4, 2024 — A new study found increased coronary vessel wall thickness that was significantly associated with ...

Time April 04, 2024
arrow
News | Radiation Oncology

April 2, 2024 — In a 10-center study, microwave ablation offered progression free survival rates and fewer complications ...

Time April 02, 2024
arrow
News | Radiation Therapy

March 28, 2024 — RefleXion Medical, Inc., a therapeutic oncology company, and Limbus AI, Inc., a provider of software ...

Time March 28, 2024
arrow
News | ACR

March 21, 2024 — The Advanced Research Projects Agency for Health (ARPA-H) has appointed American College of Radiology ...

Time March 21, 2024
arrow
Subscribe Now